Edition:
United Kingdom

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

2.15USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
27,152
52-wk High
$2.71
52-wk Low
$1.80

Chart for

About

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $64.74
Shares Outstanding(Mil.): 30.11
Dividend: --
Yield (%): --

Financials

  SPHS.OQ Industry Sector
P/E (TTM): -- 30.61 33.50
EPS (TTM): -0.29 -- --
ROI: -33.21 13.57 13.17
ROE: -78.52 15.25 14.98

BRIEF-Sophiris Bio Q4 Loss Per Share $0.13

* SOPHIRIS BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS

21 Mar 2018

BRIEF-Sophiris Bio Announces Complete Enrollment In Phase 2B Topsalysin Study

* SOPHIRIS BIO ANNOUNCES COMPLETE ENROLLMENT IN PHASE 2B TOPSALYSIN STUDY OF LOCALIZED PROSTATE CANCER Source text for Eikon: Further company coverage:

11 Dec 2017

BRIEF-Sophiris Bio posts Q3 loss per share $0.09

* Sophiris Bio reports third quarter financial results and key corporate highlights

09 Nov 2017

BRIEF-bluebird bio reports qtrly ‍loss per share $1.73​

* bluebird bio reports third quarter 2017 financial results and recent operational progress

01 Nov 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,592 +12.00
Pfizer Inc. (PFE.N) $36.35 -0.14
Merck & Co., Inc. (MRK.N) $58.51 -0.41
Sanofi SA (SASY.PA) €65.60 -0.21
GlaxoSmithKline plc (GSK.L) 1,407.40 -14.20
Eli Lilly And Co (LLY.N) $78.95 -0.77

Earnings vs. Estimates